背景:骨质疏松症的特征是骨强度降低和骨折风险增加。骨质疏松相关的骨折与发病率增加有关,死亡率,功能障碍,获得医疗保健,医疗费用,降低了生活质量。因此,预防骨质疏松性椎体压缩骨折(OVCF)很重要。次级OVCF通常发生在第一次OVCF之后。
目的:本研究旨在确定第一次OVCF后第二次OVCF的危险因素。
方法:回顾性观察研究。
方法:本研究纳入了2000年1月1日至2019年12月31日期间来自单一机构的77例首次OVCF患者。
方法:所有病例均观察到以下数据:患者人口统计学,骨矿物质密度,和骨盆参数。
方法:我们回顾性分析了2000年1月1日至2019年12月31日首次OVCF患者。人口因素,药物(口服双膦酸盐,唑来膦酸,denosumab),骨矿物质密度(BMD),体重指数(BMI),使用双能X射线吸收法测量躯干的脂肪和肌肉量,和骨盆参数(腰椎前凸,骶骨斜坡,骨盆倾斜,骨盆发病率减去腰椎前凸)进行了调查。
结果:在178名患有OVCF的患者中,68(38.2%)患有第二次OVCF。患者随访时间>2年,平均戴牙套6个月。平均年龄71.9±8.63岁,平均BMDT评分为-3.1±1.09,平均BMI为23.3±2.96.比较那些有和没有第二个OVCF的,BMDT评分和躯干肌肉质量与脂肪比越小,发生第二次OVCF的可能性越大(P<0.05)。注射药物组第二次OVCF例数少于口服组(P<0.05)。这些组之间的放射学参数没有显着差异。
结论:患有第二次OVCF的患者在第一次OVCF后平均有21.3个月。第二次OVCF的危险因素是股骨T得分低,和低M/F比的树干,android和gynoid区域。对于OVCF患者,注射药物可能是可取的。
BACKGROUND: Osteoporosis is characterized by decreased bone strength and an increased risk of fracture. Osteoporosis-related fractures are associated with increased morbidity, mortality, dysfunction, access to health care, health-care costs, and reduced quality of life. Therefore, preventing osteoporotic vertebral compression fractures (OVCF) is important. Secondary OVCFs often occur after the first OVCF.
OBJECTIVE: This study aimed to identify risk factors for a second OVCF after a first OVCF.
METHODS: Retrospective observational study.
METHODS: One hundred seventy-eight patients from a single institution who had their first OVCF between January 1, 2000 and December 31, 2019 were enrolled in this study.
METHODS: The following data were observed for all cases: patient demographics, bone mineral density, and pelvic parameters.
METHODS: We retrospectively reviewed patients from a single institution who had their first OVCF between January 1, 2000 and December 31, 2019. Demographic factors, medication (oral bisphosphonate, zoledronic acid, denosumab), bone mineral density (BMD), body mass index (BMI), fat, and muscle amount of the trunk using dual-energy X-ray absorptiometry (DEXA), and pelvic parameters (lumbar lordosis, sacral slope, pelvic tilt, pelvic incidence minus lumbar lordosis) were investigated.
RESULTS: Of 178 patients who had an OVCF, 68 (38.2%) had a second OVCF. Patients were followed up for >2 years and wore braces for an average of 6 months. The mean age was 71.9±8.63 years, mean BMD T-score was -3.1±1.09, and mean BMI was 23.3±2.96. Comparing those with and without a second OVCF, the smaller the BMD T-score and trunk muscle mass to fat ratio, the more likely a second OVCF occurred (p<.05). There were fewer second OVCF cases in the injection medication group than in the peroral group (p<.05). There were no significant differences in radiologic parameters between these groups.
CONCLUSIONS: Patients who had a second OVCF had an average of 21.3 months after the first OVCF. Risk factors for a second OVCF are low T-scores in the femur, and low M/F ratio of the trunk, android, and
gynoid regions. For patients with an OVCF, injection medications may be advisable.